Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 3,754 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phase duration Clear all
Active, not recruiting Phase 1 Interventional

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT03498378
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Avelumab, Palbociclib, Cetuximab
Drug
Lead sponsor
Kathryn Gold
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 31, 2026, 3:33 AM EDT
Terminated Phase 3 Interventional Results available

Study of TV-1106 in Growth Hormone-Deficient Adults

NCT02410343
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
TV-1106, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
25
States / cities
Artesia, California • Fountain Valley, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 31, 2026, 3:33 AM EDT
Terminated Phase 2 Interventional Results available

Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer

NCT00250835
View directory record Official record
Conditions
Rectal Cancer
Interventions
Chemotherapy, Celecoxib, and Radiation
Other
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
3
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 31, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia

NCT03609593
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Bendamustine, Venetoclax, Rituximab
Drug
Lead sponsor
Nicole Lamanna
Other
Eligibility
18 Years to 99 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 31, 2026, 3:33 AM EDT
Completed Not applicable Interventional Results available

Performance and Safety of Biology-Guided Radiotherapy Using the RefleXion Medical Radiotherapy System (BIOGUIDE-X)

NCT04788147
View directory record Official record
Conditions
Cancer, Tumor, Solid, Cancer, Lung, Cancer, Bone, Metastasis to Lung, Metastasis to Bone
Interventions
RMRS IDE Device
Device
Lead sponsor
RefleXion Medical
Industry
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Stanford, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 31, 2026, 3:33 AM EDT
Recruiting Phase 2 Interventional

Using Smartphones to Improve Physical Activity Levels of Individuals With Spinal Cord Injury

NCT05317832
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
WI program, WI Program Reminder, JITAI Goal Setting, JITAI physical activity message, Notification EMA, End of day EMA, Wake up time EMA, Weekly PA Information, Daily PA Information
Behavioral · Other
Lead sponsor
Temple University
Other
Eligibility
18 Years to 75 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 31, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Peanut Epicutaneous Phase II Immunotherapy Clinical Trial

NCT01904604
View directory record Official record
Conditions
Peanut Hypersensitivity, Food Hypersensitivity, Hypersensitivity, Hypersensitivity, Immediate
Interventions
Placebo Viaskin® Patch, Low-dose DBV712 Viaskin® Patch, High-dose DBV712 Viaskin® Patch
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 25 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Oct 31, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03412747
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
23
States / cities
Glendale, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 31, 2026, 3:33 AM EDT
Completed No phase listed Observational Results available

Remote Assessment of Physical Function

NCT04339959
View directory record Official record
Conditions
Cancer Survivors
Interventions
Remote Assessment of Physical Function with Direct Observation, Remote Assessment of Physical Function
Other
Lead sponsor
University of New Mexico
Other
Eligibility
60 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 31, 2026, 3:33 AM EDT
Active, not recruiting Phase 4 Interventional Results available

Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

NCT06372496
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
36
States / cities
Centreville, Alabama • Little Rock, Arkansas • Newport Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 3:33 AM EDT
Completed Phase 1 Interventional

Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)

NCT03063762
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Atezolizumab, Bevacizumab, RO6874281
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
New Haven, Connecticut • Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 31, 2026, 3:33 AM EDT
Suspended No phase listed Observational

Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring

NCT04906369
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Biospecimen Collection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 31, 2026, 3:33 AM EDT
Active, not recruiting Phase 1 Interventional

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

NCT04323956
View directory record Official record
Conditions
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Indolent Non-Hodgkin Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Parsaclisib, Pegfilgrastim, Polatuzumab Vedotin, Prednisone, Rituximab, Vincristine Sulfate
Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 31, 2026, 3:33 AM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol

NCT04662073
View directory record Official record
Conditions
Covid19
Interventions
Camostat, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Pleasanton, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 31, 2026, 3:33 AM EDT
Completed Phase 2 Interventional

Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)

NCT05996835
View directory record Official record
Conditions
Acute Kidney Injury Due to Sepsis
Interventions
TIN816 70 mg lyophilisate powder, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 31, 2026, 3:33 AM EDT
Not listed Early Phase 1 Interventional

Biofeedback Retention in Individuals With AKA

NCT05126485
View directory record Official record
Conditions
Amputation of Knee, Back Pain, Osteo Arthritis Knee
Interventions
Haptic Biofeedback from SageMotion Biofeedback System
Device
Lead sponsor
San Jose State University
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Palo Alto, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 31, 2026, 3:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT05032183
View directory record Official record
Conditions
Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Lymphoblastic Lymphoma, Refractory T Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Filgrastim-sndz, Leucovorin, Mercaptopurine, Mesna, Methotrexate, Pegfilgrastim, Prednisone, Rituximab, Tagraxofusp-erzs, Vincristine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 31, 2026, 3:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cervical Cancer Prevention for Black Adults

NCT04927494
View directory record Official record
Conditions
Cervical Cancer
Interventions
Health is Wealth: A Cervical Health Program
Behavioral
Lead sponsor
Adebola Adegboyega
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 31, 2026, 3:33 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

NCT07502508
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
icovamenib 100 mg, Placebo
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Canoga Park, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 3:33 AM EDT
Terminated Phase 1 Interventional

Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection

NCT01560468
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
ITX 5061
Drug
Lead sponsor
Schiano, Thomas D., MD
Other
Eligibility
18 Years to 72 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 31, 2026, 3:33 AM EDT
Terminated Not applicable Interventional Results available

Use of the DJO Brace With the Motion Intelligence Platform in the Postoperative Total Knee Arthroplasty Patient

NCT04655703
View directory record Official record
Conditions
Total Knee Replacement
Interventions
DJO X4 brace with Motion Intelligence Platform
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Syosset, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 31, 2026, 3:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Using Mobile Technology to Enhance Multisystemic Therapy (MST) Outcomes

NCT02320903
View directory record Official record
Conditions
Child Behavior Disorders
Interventions
VillageWhere App
Device
Lead sponsor
Evidence-Based Practice Institute, Seattle, WA
Industry
Eligibility
13 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 31, 2026, 3:33 AM EDT
Active, not recruiting Phase 1 Interventional

Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

NCT01044069
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia
Interventions
gene-modified T cells targeted
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 31, 2026, 3:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

NCT04305041
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, Quavonlimab, Vibostolimab, Lenvatinib, ATRA
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
13
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 31, 2026, 3:33 AM EDT